Switch theme
Sign up to access all valuation multiples
Huaxia Eye Hospital Group Co Ltd is a ophthalmic medical chain group in China. It offers ophthalmology specialist medical services.
2004
n/a
LTM Revenue $585M
LTM EBITDA $128M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Huaxia Eye Hospital Group has a last 12-month revenue (LTM) of $585M and a last 12-month EBITDA of $128M.
In the most recent fiscal year, Huaxia Eye Hospital Group achieved revenue of $559M and an EBITDA of $127M.
Huaxia Eye Hospital Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Huaxia Eye Hospital Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $585M | XXX | $559M | XXX | XXX | XXX |
| Gross Profit | $259M | XXX | $247M | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $128M | XXX | $127M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $95.5M | XXX | $88.3M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $65.9M | XXX | $59.5M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Huaxia Eye Hospital Group's stock price is CNY 19 (or $3).
Huaxia Eye Hospital Group has current market cap of CNY 15.8B (or $2.2B), and EV of CNY 12.9B (or $1.8B).
See Huaxia Eye Hospital Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $2.2B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Huaxia Eye Hospital Group has market cap of $2.2B and EV of $1.8B.
Huaxia Eye Hospital Group's trades at 3.2x EV/Revenue multiple, and 14.0x EV/EBITDA.
Equity research analysts estimate Huaxia Eye Hospital Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Huaxia Eye Hospital Group has a P/E ratio of 33.3x.
See valuation multiples for Huaxia Eye Hospital Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 13.9x | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBIT | 18.7x | XXX | 20.2x | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 33.3x | XXX | 36.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 23.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHuaxia Eye Hospital Group's last 12 month revenue growth is 11%
Huaxia Eye Hospital Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Huaxia Eye Hospital Group's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Huaxia Eye Hospital Group's rule of X is 50% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Huaxia Eye Hospital Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | -10% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Huaxia Eye Hospital Group acquired XXX companies to date.
Last acquisition by Huaxia Eye Hospital Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Huaxia Eye Hospital Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Huaxia Eye Hospital Group founded? | Huaxia Eye Hospital Group was founded in 2004. |
| Where is Huaxia Eye Hospital Group headquartered? | Huaxia Eye Hospital Group is headquartered in China. |
| Is Huaxia Eye Hospital Group publicy listed? | Yes, Huaxia Eye Hospital Group is a public company listed on SHE. |
| What is the stock symbol of Huaxia Eye Hospital Group? | Huaxia Eye Hospital Group trades under 301267 ticker. |
| When did Huaxia Eye Hospital Group go public? | Huaxia Eye Hospital Group went public in 2022. |
| Who are competitors of Huaxia Eye Hospital Group? | Similar companies to Huaxia Eye Hospital Group include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Huaxia Eye Hospital Group? | Huaxia Eye Hospital Group's current market cap is $2.2B |
| What is the current revenue of Huaxia Eye Hospital Group? | Huaxia Eye Hospital Group's last 12 months revenue is $585M. |
| What is the current revenue growth of Huaxia Eye Hospital Group? | Huaxia Eye Hospital Group revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Huaxia Eye Hospital Group? | Current revenue multiple of Huaxia Eye Hospital Group is 3.1x. |
| Is Huaxia Eye Hospital Group profitable? | Yes, Huaxia Eye Hospital Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Huaxia Eye Hospital Group? | Huaxia Eye Hospital Group's last 12 months EBITDA is $128M. |
| What is Huaxia Eye Hospital Group's EBITDA margin? | Huaxia Eye Hospital Group's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Huaxia Eye Hospital Group? | Current EBITDA multiple of Huaxia Eye Hospital Group is 13.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
